Product
SAR439859
1 clinical trial
1 indication
Indication
Breast CancerClinical trial
A Randomized, Multicenter, Double-blind Phase 3 Study of Amcenestrant (SAR439859) Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced DiseaseStatus: Terminated, Estimated PCD: 2022-06-28